Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15960943 | 0.92 | ESR1 (0.76) | ESR1ESR2 | |
| SCHEMBL16346286 | 0.85 | ESR1 (0.63) | ESR1ESR2 | |
| SCHEMBL14613446 | 0.82 | ESR1 (0.76) | ESR1ESR2 | |
| SCHEMBL15953185 | 0.80 | ESR1 (1.00) | ESR1 | |
| SCHEMBL15953186 | 0.80 | ESR1 (1.00) | ESR1 | |
| SCHEMBL15953751 | 0.80 | ESR1 (1.00) | ESR1 | |
| SCHEMBL15953748 | 0.80 | ESR1 (1.00) | ESR1 | |
| SCHEMBL25079117 | 0.80 | ESR1 (0.70) | ESR1ESR2 | |
| SCHEMBL22871556 | 0.80 | ESR1 (0.81) | ESR1ESR2 | |
| SCHEMBL20442689 | 0.79 | ESR1 (0.55) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931317-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2018-04-03 | — | — | US | disclosed |
| US-20170112805-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-8877801-B2 | Compounds and compositions as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20140235660-A1 | COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112805-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, CYP19A1, GPER1 | ESR1 1/4885ESR2 4/4885 |
| US-20140235660-A1 | COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.